What is HC Wainwright’s Forecast for TARS Q1 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a report issued on Wednesday, February 26th. HC Wainwright analyst O. Livnat expects that the company will post earnings per share of ($0.80) for the quarter. HC Wainwright has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q1 2025 earnings at ($0.80) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.59) EPS, FY2025 earnings at ($1.59) EPS, FY2026 earnings at $1.52 EPS, FY2026 earnings at $1.52 EPS, FY2027 earnings at $4.14 EPS and FY2027 earnings at $4.14 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.08. The business had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.

Several other research analysts also recently issued reports on TARS. Guggenheim reaffirmed a “buy” rating and issued a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday. Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Barclays cut their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, The Goldman Sachs Group upped their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $61.33.

Tarsus Pharmaceuticals Stock Up 2.3 %

Shares of TARS opened at $43.55 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -11.43 and a beta of 1.01. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The stock has a fifty day moving average of $51.14 and a 200-day moving average of $43.00.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter worth $25,000. GF Fund Management CO. LTD. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth about $44,000. R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $53,000. Quarry LP bought a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $166,000. Finally, HighTower Advisors LLC acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth approximately $207,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.